Dominic Marasco Joins Luventix Advisory Board
Luventix, an innovator in cutting-edge Intelligent Disease Diagnostics, proudly announces that Dominic Marasco, RPh, has joined its Advisory Board.
Mr. Marasco brings a wealth of experience spanning over 25 years in the pharmaceutical, healthcare, and private equity sectors. Known for his strategic vision and expertise in identifying high-value partnerships, Mr. Marasco has a proven track record of fostering collaborations that drive growth and innovation. His unique perspective, honed through years of executive leadership and private equity involvement, positions him as a key asset to Luventix’s strategic initiatives and global expansion efforts.
"We are excited to welcome Dominic Marasco to our Advisory Board," said George Holmes, CEO of Luventix. "His exceptional ability to identify strategic opportunities and build impactful partnerships will be pivotal as we continue to grow and deliver transformative solutions."
About Luventix
Luventix is a medical diagnostics company utilizing a simple, non-invasive urine test to detect and diagnose diseases through metabolomics modeling. By leveraging proprietary advanced machine learning (ML) modeling techniques, Luventix has the unique ability to analyze data and pinpoint disease-specific signatures within a Digital Twin, bridging the gap between diagnostics and therapeutics, revolutionizing clinical trial recruitment and enabling companion diagnostics as an integral endpoint.
With a commitment to innovation, collaboration, and excellence, Luventix is redefining industry standards and making a meaningful impact on healthcare outcomes. By combining cutting-edge technology with strategic partnerships, Luventix aims to transform the landscape of personalized medicine and accelerate the delivery of life-changing solutions. For more information, please visit www.luventix.com
Media Contact:
